More than 5,000 people have been studied to verify that blood tests for stomach cancer are expected to provide non-invasional early screening.

On the 24th, the National University of Singapore announced that a joint research team consisting of clinicians and scientists from the National University Medical Organization (NUHS) and researchers from the Institute of Biotechnology and Medical Diagnostics and Development of the Singapore Science and Technology Research Council, as well as researchers from the biotechnology company MiRXES, has successfully developed a blood test for stomach cancer.
87 percent of patients with gastric cancer, including 87.5 percent of stage 1 gastric cancer patients, were detected in clinical studies involving more than 5,000 participants.
study was published in the medical journal Gut.
is the world's third leading cause of death, according to the World Health Organization.
china, stomach cancer is the second largest cancer after lung cancer, with morbidity and mortality accounting for 44% and 50% of the global incidence and death rate of stomach cancer, respectively.
80% of Chinese gastric cancer patients are at an advanced stage at the time of diagnosis, resulting in a higher mortality rate for the cancer.
endoscope is currently used to diagnose stomach cancer standard method, however, because endoscopy is invasive, resulting in many patients even if symptoms are not willing to accept endoscopy.
study of 578 microRNA (miRNA) samples from 682 patients, the team successfully found biomarkers consisting of 12 miRNAs that distinguish gastric cancer patients from ordinary patients with an accuracy of more than 92%.
based on this group of 12 miRNA biomarkers, the team successfully developed a clinically compliant blood test kit for stomach cancer.
blood tests for stomach cancer were carried out in the laboratory and the results could be produced in about three hours and a report could be given to patients and doctors within a week.
it provides a non-invasive early screening test for stomach cancer.
from 2013 to 2018, the team validated the test kit at several hospitals in Singapore, involving more than 5,000 patients.
the world's most comprehensive assessment to date of circulating miRNA as a biomarker for gastric cancer detection, according to a press release.
study showed that by comparing it with endoscopy and biopsy, the blood test was highly sensitive and was able to detect 87 percent of gastric cancer patients, including 87.5 percent with stage 1 stomach cancer, regardless of the stage of the participant's tumor or differences in their age, gender or race.
"Most gastric cancer patients are terminally ill at the time of diagnosis, with a five-year survival rate of less than 5 per cent," explains Professor Su Boxin, Director of Oncology surgery and Senior Consultant Physician at the National University of Singapore Cancer Centre, based on miRNA blood tests (Photo: Reference.
, if you want to reduce the death rate from stomach cancer, an effective solution is to diagnose gastric cancer patients as soon as possible so that they can be treated in a timely manner.
non-invasive blood test is a breakthrough in the diagnosis of stomach cancer and has the potential to be an effective screening test for early detection of gastric cancer patients.
" kit, called GASTROClear, was successfully certified with the EU CE mark in 2017 and approved by the Singapore Health Sciences Authority in 2019.
MiRXES is also conducting clinical studies in China and Japan to seek regulatory approval for the use of GASTROClear.
: Singapore clinicians and scientists have successfully developed blood tests for stomach cancer. Retrieved October 23, 2020, from Bok Yan So et al., (2020). Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population. Gut, follow medicinalconde on WeChat Public No.